Ibuprofen is a non-steroidal anti-inflammatory drug with antipyretic and analgesic effects, and the market size is huge
.
In 2021, the sales of ibuprofen in the hospital have reached 1.
1 billion yuan, and it is still showing a growth trend
.
According to data from the State Medical Products Administration, ibuprofen products produced by more than 360 pharmaceutical companies in China have been approved
.
Recently, with the adjustment of prevention and control policies in many places, many consumers have appeared a "hoarding tide", ibuprofen has become one of the main products on the "hoarding of drugs" list, in this context, related manufacturers have also attracted the attention
of many institutions and investors.
Xinhua Pharmaceutical
Xinhua Pharmaceutical also replied to investors on the interactive platform on December 5, the company is the world's important antipyretic and analgesic API manufacturers, including ibuprofen, aspirin, metamizole sodium, aminopyrine, antipyrine, isopropyl antipyrine, tramadol, meloxicam and other varieties, the market competitiveness is very obvious
.
The actual market share of the company ibuprofen is close to 40%.
In addition, on November 14, Xinhua Pharmaceutical also told investors that the company's ibuprofen is mainly exported to high-end markets in Europe and the United States, and after years of accumulation, it has significant advantages
in scale, quality, scientific and technological progress, industrial chain support, and multi-specification granularity.
In China, most ibuprofen preparation manufacturers have conducted consistency evaluation correlation review with the company's ibuprofen APIs, and market demand can be guaranteed
.
Hendy Pharmaceuticals
Hendi Pharmaceutical said on the investor interactive platform on December 5 that the current production capacity of the company's ibuprofen API is 3,500 tons / year, and the current production and operation are normal, and the specific situation can pay attention to the relevant announcements
disclosed by the company.
According to Hengdi Pharmaceutical's reply on the investor interactive platform on November 8, the company is one of the world's major manufacturers of
non-steroidal anti-inflammatory APIs industry, especially ibuprofen APIs and dextroibuprofen APIs.
In China, the production and sales scale of the company's ibuprofen API is slightly lower than that of Xinhua Pharmaceutical, and its main foreign competitors include the United States St.
Lecote International Group, Germany's BASF, India's SOLARA and India's IOL
.
Rundu shares
Rundu replied to investors on November 15 that the company's product ibuprofen sustained-release capsules are suitable for relieving mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, and dysmenorrhea
.
It is also used for fever
caused by the common cold or influenza.
On November 17, the company said on the interactive platform that the production capacity of the company's product ibuprofen sustained-release capsules can meet the current sales demand
.
CR Sanjiu
China Resources Sanjiu recently said in the research activities disclosed that the company's ibuprofen suspension has been approved, is organizing production, and the official marketing is expected to be in mid-December
.
The company believes that the product has certain development potential
in the future.
Dori Pharmaceutical
Dori Pharma said on the interactive platform on November 25 that the company's ibuprofen suspension has been approved and has the corresponding production conditions
.
Ibuprofen suspension is used for fever caused by the common cold or influenza in children, and also for relieving mild to moderate pain in children such as headache, arthralgia, migraine, toothache, muscle pain, neuralgia
.
On December 2, the company replied to investors again that the company's ibuprofen suspension and bicarbonate Nallinger have obtained production approvals and are currently promoting sales introduction
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
